探究安罗替尼靶向治疗联合化疗治疗晚期乳腺癌的临床疗效  

The clinical efficacy of anlotinib-targeted therapy combined with chemotherapy for the treatment of advanced breast cancer

作　　者：杨帆[1] 蒋鹏[1] 褚丽莎[1] YANG Fan;JIANG Peng;CHU Li-sha(Second Department of Oncology,Tengzhou Central People's Hospital,Tengzhou 277500,China)

机构地区：[1]滕州市中心人民医院肿瘤二科,277500

出　　处：《中国实用医药》2024年第21期104-107,共4页China Practical Medicine

摘　　要：目的 分析安罗替尼靶向治疗联合化疗治疗晚期乳腺癌的临床效果。方法 选取晚期乳腺癌患者76例,采用数字随机表法分为观察组和对照组,每组38例。对照组接受化疗治疗,观察组采用安罗替尼靶向治疗联合化疗治疗。比较两组患者近期疗效、治疗期间不良反应发生率及身体健康状况评分。结果 治疗前,观察组和对照组的卡氏功能状态量表(KPS)评分比较差异不明显(P>0.05);治疗后,观察组KPS评分(87.63±9.86)分高于对照组的(76.84±8.35)分,组间差异有统计学意义(t=5.148,P<0.05)。观察组客观缓解率(ORR)为68.42%,高于对照组的44.74%,组间差异有统计学意义(χ^(2)=4.338,P<0.05)。观察组高血压发生率36.84%、肝功能异常发生率52.63%、血脂异常发生率42.11%均低于对照组的15.79%、26.32%、21.05%,组间差异有统计学意义(χ^(2)=4.343、5.507、3.897, P<0.05)。两组患者骨髓抑制、蛋白尿发生率比较差异不明显(P>0.05)。结论 晚期乳腺癌通过安罗替尼靶向治疗联合化疗治疗效果更佳,能够提高肿瘤的控制率,改善患者身体健康状况。Objective To analyze the clinical effect of anlotinib-targeted therapy combined with chemotherapy for the treatment of advanced breast cancer.Methods 76 patients with advanced breast cancer were selected and divided into an observation group and a control group according to random numerical table method,each consisting of 38 patients.The control group received chemotherapy,and the observation group used anlotinib-targeted therapy combined with chemotherapy.The short-term efficacy,incidence of adverse reactions during treatment,and physical health scores of the two groups were compared.Results Before treatment,there was no significant difference in Karnofsky performance status scale(KPS)score between the observation group and the control group(P>0.05).After treatment,KPS score of(87.63±9.86)points in the observation group was higher than(76.84±8.35)points in the control group,and the difference between groups was statistically significant(t=5.148,P<0.05).The objective response rate(ORR)of 68.42%in the observation group was higher than 44.74%in the control group,and the difference between groups was statistically significant(χ^(2)=4.338,P<0.05).The incidence of hypertension(36.84%),abnormal liver function(52.63%)and dyslipidemia(42.11%)in the observation group were lower than 15.79%,26.32%and 21.05%in the control group,and the differences between groups were statistically significant(χ^(2)=4.343,5.507,3.897;P<0.05).There were no significant differences in the incidence of myelosuppression and proteinuria between the two groups(P>0.05).Conclusion Anlotinib-targeted therapy combined with chemotherapy shows better effect for advanced breast cancer,which can improve the tumor control rate and improve the health status of patients.

关 键 词：晚期乳腺癌 安罗替尼 靶向治疗 化疗 临床疗效 

分 类 号：R737.9[医药卫生—肿瘤]